Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. A company within the industry that increased today was Medivation ( MDVN), up 12.2%. On the negative front, top decliners within the industry include GlaxoSmithKline ( GSK), down 1.9%, Sanofi ( SNY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $1.44 (1.8%) to $80.74 on average volume. Thus far, 730,773 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $77.85-$81.08 after having opened the day at $78.56 as compared to the previous trading day's close of $79.30.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.6 billion and is part of the health care sector. Shares are up 6.7% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $1.36 (1.0%) to $134.16 on light volume. Thus far, 289,338 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $130.63-$134.35 after having opened the day at $131.89 as compared to the previous trading day's close of $132.80.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $43.6 billion and is part of the health care sector. Shares are up 13.1% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Illumina ( ILMN) is up $4.97 (3.4%) to $149.50 on heavy volume. Thus far, 2.3 million shares of Illumina exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $140.05-$154.99 after having opened the day at $142.98 as compared to the previous trading day's close of $144.53.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $17.7 billion and is part of the health care sector. The company has a P/E ratio of 165.0, above the S&P 500 P/E ratio of 17.7. Shares are up 30.7% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $6.27 (2.2%) to $284.94 on average volume. Thus far, 513,720 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 836,000 shares. The stock has ranged in price between $276.05-$286.72 after having opened the day at $277.63 as compared to the previous trading day's close of $278.67.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $26.4 billion and is part of the health care sector. The company has a P/E ratio of 37.9, above the S&P 500 P/E ratio of 17.7. Shares are up 1.2% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.92 (2.1%) to $45.02 on heavy volume. Thus far, 6.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $44.75-$45.98 after having opened the day at $45.15 as compared to the previous trading day's close of $44.10.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $37.0 billion and is part of the health care sector. The company has a P/E ratio of 19.4, above the S&P 500 P/E ratio of 17.7. Shares are up 10.1% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%